Goltor (Simvastatin, Ezetimibe)

Goltor is indicated for the treatment of lipid disorders where a single‑agent approach has not achieved target cholesterol levels.

• Adjunct therapy for primary hypercholesterolemia when diet and lifestyle changes alone are insufficient.
• Management of mixed dyslipidemia characterized by elevated LDL‑cholesterol and triglycerides.
• Secondary prevention of cardiovascular events in patients with established atherosclerotic disease.
• Use in adults who require additional LDL‑cholesterol reduction beyond that achieved with a statin alone.

The safety profile of Goltor reflects the combined effects of simvastatin and ezetimibe, with side effects ranging from mild to rare serious events.

Common

• Headache or dizziness, often transient and mild.
• Muscle aches, cramps, or generalized weakness without loss of strength.
• Abdominal discomfort, nausea, or diarrhea that usually resolves with continued therapy.
• Elevated liver enzymes detected on routine laboratory testing.
• Fatigue or general malaise reported by some patients.
• Constipation or mild gastrointestinal upset.

Serious

• Severe muscle injury (rhabdomyolysis) presenting with muscle pain, dark urine, or acute kidney injury.
• Significant liver injury manifested as jaundice, hepatitis, or marked transaminase elevation.
• Allergic reactions including rash, angioedema, or anaphylactic shock.

When prescribing Goltor, clinicians should evaluate patient history and monitor laboratory parameters to minimize risk.

• Assess baseline liver function tests and repeat periodically during treatment.
• Screen for a history of muscle disorders, especially when combined with other lipid‑lowering agents.
• Use caution in patients with renal impairment or hypothyroidism, which can increase muscle toxicity.
• Avoid use during pregnancy and lactation unless the potential benefit outweighs the risk.
• Consider drug interactions with strong CYP3A4 inhibitors that may raise simvastatin concentrations.
• Educate patients to report unexplained muscle pain, weakness, or dark urine promptly.

Goltor may interact with several medications; understanding these interactions helps maintain efficacy and safety.

Avoid

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors) – may increase simvastatin levels and risk of rhabdomyolysis.
• Cyclosporine – enhances both simvastatin and ezetimibe exposure, raising toxicity risk.
• Grapefruit juice – can elevate simvastatin concentrations and should be avoided.

Use with caution

• Anticoagulants such as warfarin – may require closer INR monitoring.
• Fibrates (gemfibrozil, fenofibrate) – combined use can increase muscle‑related adverse events.
• Niacin – may augment risk of hepatotoxicity when used together.